Form 4: Caribou Biosciences Director Acquires Options in Recent Transaction

Director David Lee Johnson acquired options to purchase 40,500 shares of Caribou Biosciences common stock in a transaction dated February 20, 2025.

Summary

• On February 20, 2025, David Lee Johnson, a director of Caribou Biosciences, Inc., acquired options to purchase 40,500 shares of the company's common stock.
• The exercise price of the options is $1.41 per share.
• The options vest monthly, with one-twelfth of the shares vesting on each monthly anniversary of the grant date, and will be fully vested by February 20, 2026, contingent upon continued service to the Issuer.
• The options expire on February 19, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock options, which is neither overtly positive nor negative.

Positives

• The acquisition of options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the options is contingent upon the director's continued service to the company.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who have transactions involving the company's securities. It provides transparency into the holdings and transactions of key personnel.

Comparison to Industry Standards

• Option grants to directors are a common form of compensation in publicly traded companies, particularly in the biotechnology sector.
• The vesting schedule and exercise price are typical for such grants, aligning the director's interests with those of the shareholders over the long term.
• Comparable companies in the biotech industry, such as CRISPR Therapeutics and Editas Medicine, also utilize stock options as part of their compensation packages for directors and executives.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding the director's holdings and incentives.

Key Dates

Keywords

Caribou Biosciences, CRBU, Director, David Lee Johnson, Options, Stock Options, Beneficial Ownership, Form 4, SEC Filing